Dr. Clay Siegall is the Founder, President, and CEO of Seattle Genetics, which is a biotech firm that specializes in developing targeted therapy drugs for the disease types that have not been substantially improved for decades. Dr. Clay has a Bachelor of Science in Zoology from the University of Maryland and a Ph.D. in genetics from the George Washington University.
Seattle Genetic was founded in 1998, and Dr. Siegel has led it to the apex of the intended therapy industry. He also looks into forming a partnership with Genentech, Pfizer, Bayer, and other firms.
Seattle Genetics started with only a tiny crew of researchers, but now it is a power player in the cancer research space. Dr. Siegal also has big dreams for the company she has an expansive list of drugs in the development plan. The development of this will increase the drug portfolio in the enterprise. Dr. Siegall believes that systematic chemotherapies that were the old guard for cancer treatment will soon be history. He says that these will be replaced by more tolerable and effective targeted drugs
Dr. Siegall attributes his practice to a childhood interest in medicine and technology. He also desired to overcome disease and restore health to those consigned to death. While studying zoology on campus, he also gained interest in cancer. The interest was aggravated when a family member almost died from chemotherapy. All these factors led to Dr. Siegall’s current engagement in drug development
The company makes revenue from drug sales. Seattle Genetics also makes substantial income from production partnerships and licensing processes and technologies.
Dr. Clay Siegall
Dr. Clay Siegal is the founder of Seattle Genetics, where he serves as president and CEO. He had previous experience as he worked in Bristol-Myers Squibb Pharmaceuticals Research Institute and National Institute of Health National Center. He has also made more than 70 publications and holds 15 patents. Moreover, Dr. Siegall has a Ph.D. in genetics and a B.S in Zoology. He also sits on these boards as a director in Washington: Roundtable, Alder Biopharmaceuticals, and Ultragenyx Pharmaceuticals. Additionally, Dr. Siegall also won several awards. In 2013, he won the University of Maryland alumnus of the year for natural sciences math and computer. He also won the 2012 Pacific Northwest Ernst& Young entrepreneur of the year